Sareum Holdings

SAR · AIM · Health Care · mcap £38m · 27.5p 1 open situation →

Beta Briefing, track record and signals & risks are not ready for Sareum Holdings yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Discounted equity fundraise

Open · 1

Dilutive fundraise◷ in 3 days

Discounted equity fundraise

Subscription conditionally raised; admission pending

Sareum paused AIM trading on 8 Oct 2026 to run a fundraise, and on 26 Oct 2026 announced a conditional £3.2m subscription at 14p, a c.49% discount, with warrants. Funds take SDC-1801 to Phase 2-ready and continue neuroscience work. A WRAP retail offer of up to £100k follows. Trading on AIM restored 26 Oct.

Size: c.£3.2m before expenses; 22,807,143 new shares; WRAP offer up to £100k 26 Oct 2026 ↗
Price: 14p per share 26 Oct 2026 ↗
Discount: c.49% to 27.5p close on 7 Oct 2026 26 Oct 2026 ↗
Warrants: One per subscription share, 20p exercise price, three years from Admission; rebases if later cash issue is lower 26 Oct 2026 ↗
Use of money: SDC-1801 to Phase 2-ready, neuroscience programme, working capital with R&D tax credits 26 Oct 2026 ↗
Next milestone: Admission expected 8.00 a.m. on 29 Oct 2026; final results around 30 Oct 2026 26 Oct 2026 ↗

Next: Admission of shares and result of WRAP Retail Offer · 29 Oct 2026

26 Oct 2026 Subscription conditionally raised; admission pending

Open the full view – chart and every step →

Company filings. Not investment advice.